Skip to main content
Download PDF

rs2013278 in the multiple immunological-trait susceptibility locus CD28 regulates the production of non-functional splicing isoforms

Human Genomics volume 16, Article number: 46 (2022) Cite this article

Abstract

Background

Ligation of CD28 with ligands such as CD80 or CD86 provides a critical second signal alongside antigen presentation by class II major histocompatibility complex expressed on antigen-presenting cells through the T cell antigen receptor for naïve T cell activation. A number of studies suggested that CD28 plays an important role in the pathogenesis of various human diseases. Recent genome-wide association studies (GWASs) identified CD28 as a susceptibility locus for lymphocyte and eosinophil counts, multiple sclerosis, ulcerative colitis, celiac disease, rheumatoid arthritis, asthma, and primary biliary cholangitis. However, the primary functional variant and molecular mechanisms of disease susceptibility in this locus remain to be elucidated. This study aimed to identify the primary functional variant from thousands of genetic variants in the CD28 locus and elucidate its functional effect on the CD28 molecule.

Results

Among the genetic variants exhibiting stronger linkage disequilibrium (LD) with all GWAS-lead variants in the CD28 locus, rs2013278, located in the Rbfox binding motif related to splicing regulation, was identified as a primary functional variant related to multiple immunological traits. Relative endogenous expression levels of CD28 splicing isoforms (CD28i and CD28Δex2) compared with full-length CD28 in allele knock-in cell lines generated using CRISPR/Cas9 were directly regulated by rs2013278 (P < 0.05). Although full-length CD28 protein expressed on Jurkat T cells showed higher binding affinity for CD80/CD86, both CD28i and CD28Δex2 encoded loss-of-function isoforms.

Conclusion

The present study demonstrated for the first time that CD28 has a shared disease-related primary functional variant (i.e., rs2013278) that regulates the CD28 alternative splicing that generates loss-of-function isoforms. They reduce disease risk by inducing anergy of effector T cells that over-react to autoantigens and allergens.

Background

CD28 is a 44-kDa type I transmembrane protein expressed on the majority of T cells. Ligation of CD28 with ligands such as CD80 (known as B7-1) or CD86 (known as B7-2) provides a critical second signal alongside antigen presentation by class II major histocompatibility complex (MHC) expressed on antigen-presenting cells (APCs) through the T cell antigen receptor (TCR) for naïve T cell activation [1, 2]. The membrane-proximal YMNM motif and distal PYAP motif in the cytoplasmic tail of CD28 play an important role in the activation of NFAT, AP-1, and NF-κB and the subsequent transcription of interleukin (IL)-2, which influences T cell proliferation, survival, and differentiation. Without CD28 co-stimulation, IL-2 production is lost and T cells become anergic [3,4,5]. Therefore, CD28 acts as a positive regulator of T cell function. Cell surface expression of cytotoxic T lymphocyte–associated protein 4 (CTLA4, also known as CD152), which is highly homologous to CD28, is induced by TCR stimulation and in response to IL-2 [6]. CTLA4 binds to CD80 and CD86 with a higher affinity than CD28. This causes CTLA4 to compete with CD28 for ligand acquisition and suppresses the response of effector T cells by providing inhibitory signals that override activating signals provided by CD28 [7,8,9].

Mice lacking cd28 exhibit low basal immunoglobulin levels and impaired germinal center formation, and ctla4 was shown to produce a hyperactivated and disease-causing phenotype [10,11,12]. In humans, patients with loss-of-function mutations in CTLA4 exhibit autoimmune phenotypes [13,14,15]. A number of studies using clinical samples have suggested that overexpression of CD80 and CD86 is correlated with the development of allergic and autoimmune diseases [16, 17]. Therefore, CD28 family members (CD28, CTLA4, CD80, and CD86) play an important role in the pathogenesis of various human diseases, especially those involving immunological traits.

The human CD28 gene is encoded on chromosome 2q33.2. Recent genome-wide association studies (GWASs) identified CD28 as a susceptibility gene for various immunological diseases and traits, such as lymphocyte count, eosinophil count, multiple sclerosis (MS), ulcerative colitis (UC), celiac disease, rheumatoid arthritis (RA), and asthma [18,19,20,21,22,23,24,25,26,27,28,29]. Using data from European and East Asian cohorts (10,516 cases and 20,772 controls), our research group reported the largest genome-wide meta-analysis (meta-GWAS) of primary biliary cholangitis (PBC) to date [30]. PBC is a chronic progressive cholestatic liver disease with histological features of interface hepatitis, fibrosis, ductopenia, and chronic non-suppurative destructive cholangitis. These features are due to an autoimmune reaction to the intrahepatic bile duct [31,32,33,34,35]. The higher concordance rate in monozygotic twins than in dizygotic twins and the higher estimated sibling relative risk suggest strong involvement of genetic factors in the development of PBC [36, 37]. PBC also showed an association with the CD28 locus in our meta-GWAS (Table 1). Although the existence of alternative splicing isoforms of CD28 (CD28a, CD28b, CD28c, and CD28i) was reported [38, 39], genetic variants that regulate the efficiency of alternative splicing of CD28 have not been identified. In addition, the binding affinities of splicing isoform products to CD80 and CD86 have not been clarified.

Table 1 GWAS-lead SNPs in the CD28 locus for each immunological trait
Full size table

GWAS-lead variants exhibiting the strongest associations with disease susceptibility in the CD28 locus in GWASs are not the same among immunological traits [18,19,20,21,22,23,24,25,26,27,28,29,30] (Table 1). In the present study, to identify candidate primary functional variants in the CD28 locus that contribute to various immunological traits, linkage disequilibrium (LD) mapping of GWAS-lead variants for each immunological trait was carried out using LD data for European and East Asian populations. In silico/in vitro functional analyses utilizing CRISPR/Cas9 gene-editing technology were then performed to identify primary functional variants. Finally, we attempted to elucidate the stability and ligand binding effect of alternative splicing isoforms of CD28.

Results

LD mapping with GWAS-lead variants

A total of 157, 155, 154, 154, 135, 110, 135, 137, and 158 SNPs showed r2 > 0.2 with the following GWAS-lead variants, rs4675365 (associated with lymphocyte count), rs1879877 (associated with lymphocyte count), rs4675360 (associated with eosinophil count), rs6435203 (associated with MS), rs4675370 (associated with PBC), rs3116494 (associated with UC), rs45620941 (associated with celiac disease), rs1980422 (associated with celiac disease and RA), and rs55730955 (associated with asthma), respectively, by LD mapping using combined LD data for the EAS and EUR populations (Fig. 1).

Fig. 1
figure 1

Linkage disequilibrium (LD) mapping of CD28 SNPs with GWAS-lead SNPs (combined EAS and EUR population data). SNPs shown as red and green solid dots indicate GWAS-lead SNPs and rs2013278, respectively. Horizontal line indicates the physical position of each SNP on chromosome 2 (hg38). Vertical line indicates the r2 value of each SNP with GWAS-lead SNPs

Full size image

Among the SNPs that showed r2 > 0.2 with each GWAS-lead variant, only rs4675362 and rs2013278 were shared among all immunological traits (Fig. 2, Table 2). Although the differences in LD pattern between the EAS and EUR populations were observed in six GWAS-lead SNPs (rs1879877, rs4675360, rs3116494, rs45620941, rs1980422, and rs55730955), the major ancestor in each GWAS discovery stage showed a higher r2 score with rs4675362 and rs2013278 than other ancestors in every GWAS-lead SNP (Additional file 1). Neither SNP was located in gene expression regulatory motifs such as H3K27Ac or the DNase high-sensitivity site (Additional file 2), nor was either associated with the expression level of CD28 as determined by e-QTL analysis (Additional file 3). In contrast, rs2013278 was located in the third base of the Rbfox binding motif (GCATG), which is related to the regulation of splicing [40]. Similar to many genes related to the immune system [41], CD28 reportedly encodes an alternative splicing isoform of CD28 (CD28i) [39]. Therefore, rs2013278 was selected as a candidate primary functional variant associated with multiple immunological traits in CD28.

Fig. 2
figure 2

LD of rs2013278 with each GWAS-lead SNP. Densities of red and blue boxes indicate the r2 and D’ values of rs2013278 with GWAS-lead SNPs, respectively

Full size image
Table 2 Linkage disequilibrium scores (r2) of CD28 SNPs showed r2 > 0.2 with all of GWAS top-hit SNPs for 8 diseases and traits (EAS + EUR)
Full size table

rs2013278 regulates CD28 alternative splicing

To identify the main CD28 isoforms expressed in Jurkat T cells expressing CD28 abundantly (Fig. 3a), RT-PCR analysis was performed. Using primers targeted within exon 1 and exon 4 of CD28, three amplification products were identified (Fig. 3b). By sequencing, the longer product was found to be the normal CD28 mRNA (full-length CD28; UniProtKB identifier of protein product: P10747-1), whereas the shorter products encoded alternative splicing isoforms caused by skipping of a part of exon 2 (CD28i; UniProtKB identifier of protein product: P10747-3) or a lack of all of exon 2 (CD28Δex2; UniProtKB identifier of protein product: P10747-2) (Fig. 3c). The protein products of CD28i and CD28Δex2 were thought to be deficient in a total of 85 and 119 amino acids, respectively.

Fig. 3
figure 3

Expression of endogenous CD28 splicing isoforms is regulated by rs2013278. a Endogenous expression levels of CD28 in various human cell lines. b Endogenous expression levels of CD28 splicing isoforms in Jurkat T cells. *: non-specific peak. c Exon–intron structure of each CD28 splicing isoform. d Endogenous expression levels of CD28i and CD28Δex2 were relatively decreased in the risk allele knock-in version of Jurkat T cells generated by genome editing using CRISPR/Cas9 compared with expression levels in the non-risk allele cells

Full size image

Subsequently, the rs2013278 genotype knock-in versions of cell lines constructed using the CRISPR/Cas9 system were used to assess the contribution of rs2013278 to the endogenous expression levels of each CD28 isoform. Jurkat cells were selected to knock in the rs2013278 alleles because endogenous expression of CD28 was detected (Fig. 3a). Relative expression levels of total skipping isoforms (CD28i plus CD28Δex2) compared with full-length CD28 differed significantly between the genotype knock-in Jurkat clones of rs2013278-A/A (n = 5) and -T/T (n = 5) (P < 0.05; Mann–Whitney U test) (Fig. 3d). These results indicated that rs2013278 is a primary functional variant that directly regulates the alternative splicing of CD28.

Expression of CD28 splicing isoforms

Because no anti-human CD28 antibody that recognizes the extracellular domain of CD28i and CD28Δex2 is currently available, protein expression of the C-terminal green fluorescent protein (GFP)-conjugated CD28 isoforms was assessed in transfectants of Jurkat cells by western blotting using an antibody against GFP. Although full-length CD28 and CD28i showed abundant protein expression in transfectant cells, CD28Δex2 did not (Fig. 4).

Fig. 4
figure 4

Protein expression of each CD28 splicing isoform product. Expression of GFP-conjugated CD28 isoforms was analyzed using an anti-GFP antibody. The protein product of CD28Δex2 was not detected

Full size image

Binding of CD28 splicing isoforms to the ligand CD80/CD86

Both full-length CD28 and CD28i are reportedly located on the cell surface [39]. Although ligation of CD28 with both CD80 and CD86 provides an important second signal along with antigen presentation by the class II MHC of APCs via the TCR for naïve T cell activation [1, 2], CD86 (but not CD80) is constitutively expressed on APCs and rapidly upregulated by innate stimulation of APCs [1, 42]. Concordantly, mice lacking Cd86 (but not those lacking Cd80) are unable to undergo antibody class switching and formation of the germinal center in response to adjuvant-free immunization [43]. Therefore, CD86 may play a more important role than CD80 in the initiation of immune responses. To confirm the lower binding affinity between CD28i and CD86, direct binding between C-terminal GFP-conjugated CD28i and recombinant His-tagged CD86-Fc was assessed by flow cytometry in CD28-negative HeLa cells (Fig. 3a). Cells in which full-length CD28 was strongly expressed bound directly to His-tagged CD86-Fc, but CD28i did not (Fig. 5a–c).

Fig. 5
figure 5

Binding of CD80 and CD86 with each CD28 splicing isoform product. a–c HeLa cells with transiently overexpressed GFP-conjugated CD28 and CD28i were incubated in the presence of His-tag conjugated CD86-Fc and PE-conjugated anti-His-Tag antibody. Dot plot for mock (a), CD28 (b), and CD28i (c). The horizontal and vertical axes indicate the expression of GFP-tagged CD28 isoforms and the bindings of His-tagged CD86-Fc, respectively. d, e In silico prediction of binding between CD80 and CD28 splicing isoforms. Although binding between CD80 and CD28 was predicted (d), that between CD80 and CD28i was not (e)

Full size image

In contrast, as recombinant His-tagged CD80-Fc is not currently available, direct binding between CD28i and CD80 could not be examined. Therefore, the binding affinity of CD28i for CD80 was evaluated by in silico prediction. Full-length CD28 was predicted to show higher binding affinity with CD80 in their extracellular domains (DockQ score: 0.956). However, probably because most of the extracellular domain of CD28i is missing, CD28i was predicted to show lower binding affinity for CD80 (DockQ score: 0.001) (Fig. 5d, e).

Collectively, these results indicate that both CD28i and CD28Δex2 are loss-of-function splicing isoform products that reduce disease risk by inducing anergy of effector T cells that over-react to autoantigens and allergens.

Discussion

CD28 family members, including CD28, CTLA4, CD80, and CD86, have several common structural and functional features. First, these molecules contain immunoglobulin superfamily domains in their extracellular region. The MYPPPY motif within this domain mediates the interaction between these co-stimulatory receptors and their ligands [44,45,46]. Second, alternative splicing isoforms have been reported in all of these genes [39, 47,48,49]. However, an association between the disease-related polymorphisms and alternative splicing among the CD28 family genes was reported only for CTLA4 [47]. Therefore, the present study has demonstrated for the first time that CD28 has a shared disease-related primary functional variant (i.e., rs2013278) that regulates the alternative splicing of CD28. The RNA sequence motif GCAUG is bound by Rbfox proteins, which are expressed in human T cells [40, 50, 51]. The Rbfox proteins reportedly inhibit hnRNP M-mediated suppression of splicing by forming a complex with hnRNP M, hnRNP H, hnRNP C, Matrin3, NF110/NFAR-2, NF45, and DDX5 [40]. rs2013278 probably alters the efficiency of alternative splicing of CD28 by the presence (disease-risk allele) or collapse (disease-protective allele) of the GCAUG motif.

Although the primary functional variant is sometimes the same as the GWAS-lead variant (e.g., TNFSF15 rs4979462, which is associated with PBC [52]), most other primary functional variants are not the same as the GWAS-lead variants (e.g., several SNPs associated with PBC [53,54,55,56,57]). In the present study, rs2013278, which was not a GWAS-lead variant, was identified as a primary functional variant in CD28 associated with multiple immunological traits. Among GWAS-lead variants, rs4675365 (associated with lymphocyte count) and rs6435203 (associated with MS) showed stronger LD with rs2013278 (r2 approximately 0.9). Therefore, susceptibility to MS and changes in lymphocyte count are probably affected by the single effect of rs2013278. However, this is not the case with other immunological traits. Although rs2013278 was not associated with the CD28 expression level, rs3116494, rs45620941, and rs1980422 showed relatively strong LD with rs13404978, which exhibited the strongest correlation with CD28 expression level in the e-QTL analysis (rs3116494: r2 = 0.469; rs45620941: r2 = 0.575; and rs1980422: r2 = 0.482). Incidentally, a relatively lower r2 score was observed (r2 = 0.13) between rs2013278 and rs13404978. Another possibility is that aggregation of the effects of multiple SNPs causes the lead SNPs to show the strongest association among SNPs in the gene locus (e.g., PBC susceptibility locus STAT4) [58]. Therefore, immunological traits in which rs2013278 and the GWAS-lead variant show weak LD may have other primary functional variants characteristic of each disease in the CD28 locus.

In the present study, three primarily expressed CD28 alternative splicing isoforms (full-length CD28, CD28i, and CD28Δex2) were identified. CD28i was expressed on the cell surface [39]; however, it is incapable of binding to its ligand, CD86 (Fig. 5c). Because the total amount of the CD28 isoforms was not associated with the genotype of rs2013278 (Additional file 3), the expression levels of the loss-of-function CD28 isoforms (CD28i and CD28Δex2) were inversely proportional to that of full-length CD28. Inadequate co-stimulation of CD28 and its ligands causes hyper-reactive T cells to become anergic; therefore, relatively high expression levels of full-length CD28 associated with the disease-risk allele of rs2013278 would inhibit this anergy. This assumption is consistent with the finding that overexpression of CD86 is correlated with the development of allergic and autoimmune diseases [16, 17]. Although the other ligand, CD80, is predicted not to bind CD28i by in silico analysis (Fig. 5e), experiments examining the binding of CD28i to CD80 could not be performed because recombinant His-tagged CD80-Fc is not currently available. CD86 may play a more important role in the initiation of immune responses than CD80 [1, 42, 43]; however, the weak binding of CD28i to CD80 will need to be experimentally validated in future studies. Similarly, it will be necessary to verify the downstream signaling pathways involving CD28i, such as activation of NFAT, AP-1, and NF-κB and subsequent IL-2 transcription [3,4,5]. Although the Jurkat T cell line has been reported to have damaging mutations in genes involved in T cell receptor signaling (PTEN, INPP5D, CTLA4, and SYK) [59], maintenance of genome stability (TP53, BAX, and MSH2), and O-linked glycosylation (C1GALT1C1), karyotyping and genotyping of these genes were not performed in the Jurkat T cells that were used in the present study. One limitation of the present and future studies is the similarity between cell lines and normal human T lymphocytes.

The CD28Δex2 transcript was also abundantly expressed at the mRNA level (Fig. 3b); however, the protein product of CD28Δex2 was not expressed in transfectant cells (Fig. 4). Amino acid sequence changes caused by splicing sometimes significantly affect protein structure. For example, the unstable protein product of TCF4, which is reportedly the causal gene of an undiagnosed genetic condition, is degraded in the proteasome due to splicing-associated frameshifting [60]. In contrast, the protein product of the alternative splicing isoform of CD72 (CD72Δex8), which is reportedly a susceptibility gene of systemic lupus erythematosus, is not degraded by the proteasome and accumulates in the endoplasmic reticulum [61, 62]. A new finding regarding protein expression of CD28Δex2 was obtained in the present study. The protein stability of CD28Δex2 is presumably lost due to the lack of amino acids encoded by exon 2.

CD28 family members are considered target molecules affecting immunological traits. To date, CTLA4 Ig (abatacept), which binds to CD80/CD86 and inhibits inflammatory T cell activation, has been approved by the US Food and Drug Administration to treat RA, juvenile idiopathic arthritis, and active psoriatic arthritis [63]. A CTLA4 super-agonist (ipilimumab) has been approved to treat melanoma [64]. Although a CD28 super-agonist (theralizumab TGN1412) caused cytokine storm in healthy volunteers in a first-in-human study [65], a clinical trial of a novel type of CD28 super-agonist (TAB08) has been performed [66]. CD28 was identified as a disease susceptibility gene for immunological traits [18,19,20,21,22,23,24,25,26,27,28,29,30], and these significant associations with disease susceptibility were shown in the present study to be related to alternative splicing of CD28.

Conclusion

The present study demonstrated for the first time that rs2013278, which showed stronger linkage disequilibrium with the genome-wide association study lead variants for multiple immunological traits, regulates CD28 alternative splicing that generates loss-of-function isoforms (CD28i and CD28Δex2). They reduce disease risk by inducing anergy of effector T cells that over-react to autoantigens and allergens.

Methods

In silico prediction tools and databases

The UCSC genome browser [67] was used to assess the potential functional effect of candidate functional variants on transcriptional regulation (URL: http://genome.ucsc.edu/index.html).

LD data for the East Asian (EAS) and European (EUR) populations were obtained from LDlink (URL: https://ldlink.nci.nih.gov/) [68].

Data regarding CD28 gene expression levels in various cell lines were obtained from the Human Protein Atlas (URL: https://www.proteinatlas.org/) [50, 51].

Data from the GTEx portal (version 8) were used to investigate the correlation between genotypes of all variants in the CD28 locus and gene expression levels (URL: http://gtexportal.org/home/) [69].

Binding affinities between CD80 and splicing isoforms of CD28 were evaluated based on the DockQ score [70].

Gene editing (CRISPR/Cas9)

Following the manufacturer’s instructions, guide-RNA (gRNA) target sequences (Additional file 4) were subcloned into pGuide-it-ZsGreen1 (Clontech Laboratories, Mountain View, CA). The transfection reagent Lipofectamine-3000 (Thermo-Fisher Scientific, Waltham, MA) was used to transfect Jurkat cells with gRNAs and donor DNAs for each allele of rs2013278 (Additional file 4). Transfected cell clones were incubated with RS-1 and SCR7 (Cayman Chemical, Ann Arbor, MI). A FACSAria II system (BD Biosciences, Franklin Lakes, NJ) was used to isolate positive clones from bulk transfectants.

After single-cell cloning, genomic DNA was extracted from cell clones using PureLinkâ„¢ (Thermo-Fisher Scientific). Gene editing of target sites was confirmed using Sanger sequencing (ABI prism 3730-XL) with specific primers (Additional file 4).

Quantitative RT-PCR

Total RNA was extracted from rs2013278 allele knock-in clones using an RNeasy kit (QIAGEN, Valencia CA). Next, we synthesized first-strand cDNAs using a High-Capacity cDNA Reverse Transcription kit (Thermo-Fisher Scientific). RT-PCR was performed using the primers shown in Additional file 5 and Ex Taq polymerase (Takara-bio, Kusatsu, Japan). Preliminary experiments showed that 33 cycles were optimal for achieving linear amplification of each CD28 splicing isoform. Quantitation of each transcript was performed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Differences in expression levels of CD28 isoforms in cells of the two rs2013278 genotypes (i.e., AA and TT) were analyzed using the Mann–Whitney U test. These experiments were repeated 3 times with essentially identical results.

Plasmids

cDNAs containing the entire coding region of full-length CD28, CD28i, and CD28Δex2, which do not contain nucleotides for the stop codon, were obtained by RT-PCR analysis of Jurkat cells using the specific primer pairs shown in Additional file 6. cDNAs encoding each CD28 splicing isoform were inserted into pCR-blunt II (Thermo-Fisher Scientific) and subcloned into pAcGFP1-Hyg-N1 (Takara-bio) using XhoI.

Western blotting

After transfection of the pAcGFP1-Hyg-N1 vectors, cells were lysed in RIPA buffer. Proteins in whole-cell lysates were separated by SDS-PAGE and transferred onto polyvinylidene difluoride membranes. The membranes were incubated with anti-GFP (Proteintech, Rosemont, IL) and anti-β-tubulin (Fujifilm Wako pure chemical, Osaka, Japan) antibodies. Proteins were visualized using the ECL system.

Flow cytometry

After transfection of HeLa cells with pAcGFP1-Hyg-N1 vectors, transfectants were incubated with recombinant 6 × His-tagged human B7-2/CD86-Fc Chimera (BioLegend, San Diego, CA), followed by reaction with PE-labeled mouse anti–6xHis-tag antibody (BioLegend). Cells were then analyzed by flow cytometry using a FACSAria II and a FACSVerse system (BD Biosciences). Flow cytometry data were analyzed using FlowJo software (BD Biosciences).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

APCs:

Antigen-presenting cells

BCR:

B cell antigen receptor

CTLA4:

Cytotoxic T lymphocyte-associated protein 4

GWAS:

Genome-wide association studies

GFP:

Green fluorescent protein

gRNAs:

Guide-RNAs

IgSF:

Immunoglobulin superfamily

IL:

Interleukin

LD:

Linkage disequilibrium

MHC:

Major histocompatibility complex

MS:

Multiple sclerosis

PBC:

Primary biliary cholangitis

Treg:

Regulatory T

RA:

Rheumatoid arthritis

TCR:

T cell receptor

UC:

Ulcerative colitis

References

  1. Lenschow DJ, Sperling AI, Cooke MP, Freeman G, Rhee L, Decker DC, et al. Differential up-regulation of the B7–1 and B7–2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol. 1994;153:1990–7.

    CAS  PubMed  Google Scholar 

  2. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity. 2016;4:973–88.

    Article  Google Scholar 

  3. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science. 1991;251:313–6.

    Article  CAS  PubMed  Google Scholar 

  4. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol. 1987;7:4472–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA. 1989;86:1333–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA. 1990;87:5031–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459–65.

    Article  CAS  PubMed  Google Scholar 

  8. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405–13.

    Article  CAS  PubMed  Google Scholar 

  9. Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol. 2006;177:1052–61.

    Article  CAS  PubMed  Google Scholar 

  10. Shahinian A, Pfeffer K, Lee KP, Kündig TM, Kishihara K, Wakeham A, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science. 1993;261:609–12.

    Article  CAS  PubMed  Google Scholar 

  11. Ferguson SE, Han S, Kelsoe G, Thompson CB. CD28 is required for germinal center formation. J Immunol. 1996;156:4576–81.

    CAS  PubMed  Google Scholar 

  12. Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol. 1999;163:1128–31.

    CAS  PubMed  Google Scholar 

  13. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345:1623–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018;142:1932–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lombardi V, Singh AK, Akbari O. The role of costimulatory molecules in allergic disease and asthma. Int Arch Allergy Immunol. 2010;151:179–89.

    Article  CAS  PubMed  Google Scholar 

  17. Tsuneyama K, Harada K, Yasoshima M, Kaji K, Gershwin ME, Nakanuma Y. Expression of co-stimulatory factor B7–2 on the intrahepatic bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis: an immunohistochemical study. J Pathol. 1998;186:126–30.

    Article  CAS  PubMed  Google Scholar 

  18. Chen MH, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. Cell. 2020;182:1198–213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, et al. The polygenic and monogenic basis of blood traits and diseases. Cell. 2020;182:1214–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, et al. Leveraging polygenic functional enrichment to improve GWAS power. Am J Hum Genet. 2019;104:65–75.

    Article  CAS  PubMed  Google Scholar 

  21. International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353–60.

    Article  Google Scholar 

  22. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Coleman C, Quinn EM, Ryan AW, Conroy J, Trimble V, Mahmud N, et al. Common polygenic variation in coeliac disease and confirmation of ZNF335 and NIFA as disease susceptibility loci. Eur J Hum Genet. 2016;24:291–7.

    Article  CAS  PubMed  Google Scholar 

  24. Gutierrez-Achury J, Zorro MM, Ricaño-Ponce I, Zhernakova DV, Coeliac Disease Immunochip Consortium, RACI Consortium, Diogo D, et al. Functional implications of disease-specific variants in loci jointly associated with coeliac disease and rheumatoid arthritis. Hum Mol Genet. 2016;25:180–90.

    Article  CAS  PubMed  Google Scholar 

  25. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet. 2011;43:1193–201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506:376–81.

    Article  CAS  PubMed  Google Scholar 

  27. Laufer VA, Tiwari HK, Reynolds RJ, Danila MI, Wang J, Edberg JC, et al. Genetic influences on susceptibility to rheumatoid arthritis in African-Americans. Hum Mol Genet. 2019;28:858–74.

    Article  CAS  PubMed  Google Scholar 

  28. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet. 2012;44:1336–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53:1415–24.

    Article  CAS  PubMed  Google Scholar 

  30. Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, et al. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. J Hepatol. 2021;75:572–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Nakamura M. Clinical significance of autoantibodies in primary biliary cirrhosis. Semin Liver Dis. 2014;34:334–40.

    Article  CAS  PubMed  Google Scholar 

  32. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA-DRB4* 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med. 1995;181:1835–45.

    Article  CAS  PubMed  Google Scholar 

  33. Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest. 1998;102:1831–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–73.

    Article  CAS  PubMed  Google Scholar 

  35. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet. 2011;377:1600–9.

    Article  CAS  PubMed  Google Scholar 

  36. Jones DE, Watt FE, Metcalf JV, Bassendine MF, James OF. Familial primary biliary cholangitis reassessed: a geographically based population study. J Hepatol. 1999;30:402–7.

    Article  CAS  PubMed  Google Scholar 

  37. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, et al. Primary biliary cholangitis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004;127:485–92.

    Article  PubMed  Google Scholar 

  38. Magistrelli G, Jeannin P, Elson G, Gauchat JF, Nguyen TN, Bonnefoy JY, et al. Identification of three alternatively spliced variants of human CD28 mRNA. Biochem Biophys Res Commun. 1999;259:34–7.

    Article  CAS  PubMed  Google Scholar 

  39. Hanawa H, Ma Y, Mikolajczak SA, Charles ML, Yoshida T, Yoshida R, et al. A novel costimulatory signaling in human T lymphocytes by a splice variant of CD28. Blood. 2002;99:2138–45.

    Article  CAS  PubMed  Google Scholar 

  40. Damianov A, Ying Y, Lin CH, Lee JA, Tran D, Vashisht AA, et al. Rbfox proteins regulate splicing as part of a large multiprotein complex LASR. Cell. 2016;165:606–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res. 2001;29:2850–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116–26.

    Article  CAS  PubMed  Google Scholar 

  43. Borriello F, Sethna MP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, et al. B7–1 and B7–2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity. 1997;6:303–13.

    Article  CAS  PubMed  Google Scholar 

  44. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 2002;20:29–53.

    Article  CAS  PubMed  Google Scholar 

  45. Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C, et al. Crystal structure of a soluble CD28-Fab complex. Nat Immunol. 2005;6:271–9.

    Article  CAS  PubMed  Google Scholar 

  46. Metzler WJ, Bajorath J, Fenderson W, Shaw SY, Constantine KL, Naemura J, et al. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nat Struct Biol. 1997;4:527–31.

    Article  CAS  PubMed  Google Scholar 

  47. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–11.

    Article  CAS  PubMed  Google Scholar 

  48. Kakoulidou M, Giscombe R, Zhao X, Lefvert AK, Wang X. Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation. Scant J Immunol. 2007;66:529–37.

    Article  CAS  Google Scholar 

  49. Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. A novel B7–2 (CD86) splice variant with a putative negative regulatory role. J Immunol. 2008;180:3815–23.

    Article  CAS  PubMed  Google Scholar 

  50. Uhlén M, Björling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4:1920–32.

    Article  PubMed  Google Scholar 

  51. Thul PJ, Ã…kesson L, Wiking M, Mahdessian D, Geladaki A, AitBlal H, et al. A subcellular map of the human proteome. Science. 2017;356:eaal3321.

    Article  PubMed  Google Scholar 

  52. Hitomi Y, Kawashima M, Aiba Y, Nishida N, Matsuhashi M, Okazaki H, et al. Human primary biliary cirrhosis-susceptible allele of rs4979462 enhances TNFSF15 expression by binding NF-1. Hum Genet. 2015;134:737–47.

    Article  CAS  PubMed  Google Scholar 

  53. Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, et al. POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33. Sci Rep. 2019;9:102.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Hitomi Y, Kojima K, Kawashima M, Kawai Y, Nishida N, Aiba Y, et al. Identification of the functional variant driving ORMDL3 and GSDMB expression in human chromosome 17q12-21 in primary biliary cholangitis. Sci Rep. 2017;7:2904.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Hitomi Y, Nakatani K, Kojima K, Nishida N, Kawai Y, Kawashima M, et al. NFKB1 and MANBA confer disease susceptibility to primary biliary cholangitis via independent putative primary functional variants. Cell Mol Gastroenterol Hepatol. 2019;7:515–32.

    Article  PubMed  Google Scholar 

  56. Hitomi Y, Aiba Y, Kawai Y, Kojima K, Ueno K, Nishida N, et al. rs1944919 on chromosome 11q23.1 and its effector genes COLCA1/COLCA2 confer susceptibility to primary biliary cholangitis. Sci Rep. 2021;11:4557.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Hitomi Y, Aiba Y, Ueno K, Nishida N, Kawai Y, Kawashima M, et al. rs9459874 and rs1012656 in CCR6/FGFR1OP confer susceptibility to primary biliary cholangitis. J Autoimmun. 2022;126:102775.

    Article  CAS  PubMed  Google Scholar 

  58. Gervais O, Ueno K, Kawai Y, Hitomi Y, Aiba Y, Ueta M, et al. Regional heritability mapping identifies several novel loci (STAT4, ULK4, and KCNH5) for primary biliary cholangitis in the Japanese population. Eur J Hum Genet. 2021;29:1282–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Gioia L, Siddique A, Head SR, Salomon DR, Su AI. A genome-wide survey of mutations in the Jurkat cell line. BMC Genomics. 2018;19:334.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Need AC, Shashi V, Hitomi Y, Schoch K, Shianna KV, McDonald MT, et al. Clinical application of exome sequencing in undiagnosed genetic conditions. J Med Genet. 2012;49:353–61.

    Article  CAS  PubMed  Google Scholar 

  61. Hitomi Y, Tsuchiya N, Kawasaki A, Ohashi J, Suzuki T, Kyogoku C, et al. CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B. Hum Mol Genet. 2004;13:2907–17.

    Article  CAS  PubMed  Google Scholar 

  62. Hitomi Y, Adachi T, Tsuchiya N, Honda Z, Tokunaga K, Tsubata T. Human CD72 splicing isoform responsible for resistance to systemic lupus erythematosus regulates serum immunoglobulin level and is localized in endoplasmic reticulum. BMC Immunol. 2012;13:72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Liu M, Yu Y, Hu S. A review on applications of abatacept in systemic rheumatic diseases. Int Immunopharmacol. 2021;96: 107612.

    Article  CAS  PubMed  Google Scholar 

  64. Ledford H. Melanoma drug wins US approval. Nature. 2011;471:561.

    Article  CAS  PubMed  Google Scholar 

  65. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine Storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.

    Article  CAS  PubMed  Google Scholar 

  66. Tyrsin D, Chuvpilo S, Matskevich A, Nemenov D, Römer PS, Tabares P, et al. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:45–8.

    PubMed  Google Scholar 

  67. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12:996–1006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Machiela MJ, Chanock SJ. LDlink a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31:3555–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580–5.

    Article  Google Scholar 

  70. Basu S, Wallner B. DockQ: a quality measure for protein-protein docking models. PLoS ONE. 2016;11:e0161879.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank all patients and volunteers who enrolled in the study. We also thank Ms. Yoshimi Shigemori, Ms. Ayumi Nakayama, Ms. Mayumi Ishii, Ms. Takayo Tsuchiura, Ms. Tomoko Suzuki, Ms. Nozomi Komatsuzaki, Ms. Hikari Tokunaga, Ms. Yuko Maeda, Ms. Mizuki Kobayashi (National Center for Global Health and Medicine), and Ms. Hitomi Nakamura, Ms. Yumi Ogami (Nagasaki Medical Center) for technical and administrative assistance.

Funding

This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science to Yuki Hitomi (22K08065, 19K08413), Yoshihiro Aiba (20K08370), and Minoru Nakamura (17H04169); Clinical Research from the NHO to Minoru Nakamura; Research Program for Rare/Intractable Diseases provided by the Ministry of Health, Labour, and Welfare of Japan to Minoru Nakamura; Platform Program for Promotion of Genome Medicine (19km0405205h9904) from the Japan Agency for Medical Research and Development to Katsushi Tokunaga and Masao Nagasaki; and Takeda Foundation to Yuki Hitomi.

Author information

Authors and Affiliations

  1. Department of Human Genetics, Research Institute, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan

    Yuki Hitomi, Chisato Iwabuchi, Sanami Takada & Noriko Miyake

  2. Department of Microbiology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan

    Yuki Hitomi & Makoto Tsuiji

  3. Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Omura, Japan

    Yoshihiro Aiba & Minoru Nakamura

  4. Genome Medical Science Project, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan

    Kazuko Ueno, Nao Nishida, Yosuke Kawai & Katsushi Tokunaga

  5. The Research Center for Hepatitis and Immunology, Research Institute, National Center for Global Health and Medicine, Ichikawa, Japan

    Nao Nishida

  6. Japan Science and Technology Agency (JST), Tokyo, Japan

    Minae Kawashima

  7. Human Biosciences Unit for the Top Global Course Center for the Promotion of Interdisciplinary Education and Research, Kyoto University, Kyoto, Japan

    Masao Nagasaki

  8. Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Omura, Japan

    Minoru Nakamura

  9. Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan

    Minoru Nakamura

Authors
  1. Yuki Hitomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Aiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuko Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nao Nishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yosuke Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Minae Kawashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Makoto Tsuiji
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chisato Iwabuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sanami Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Noriko Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masao Nagasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Katsushi Tokunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Minoru Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YH, MN, TK, and MN contributed to study concept and design; YH, MT, CI, and MN were involved in acquisition of data; YH, YA, KU, NN, YK, MK, MT, CI, ST, NM, MN, and MN contributed to analysis and interpretation of data; YH, NN, and MN drafted the manuscript; YH, YA, MN, KT, and MN obtained funding; and NM, MN, KT, and MN were involved in study supervision. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yuki Hitomi.

Ethics declarations

Competing interests

The authors declare that there are no known competing economic interests or personal relationships that may affect the studies reported in this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Additional tables and figures.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hitomi, Y., Aiba, Y., Ueno, K. et al. rs2013278 in the multiple immunological-trait susceptibility locus CD28 regulates the production of non-functional splicing isoforms. Hum Genomics 16, 46 (2022). https://doi.org/10.1186/s40246-022-00419-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40246-022-00419-7

Keywords

  • Immunological-trait
  • Genome-wide association study (GWAS)
  • CD28
  • Primary functional variant
  • Alternative splicing
  • Linkage disequilibrium
  • CRISPR/Cas9

Human Genomics

ISSN: 1479-7364